Table 2.
Psychiatric comorbidities in MG patients.
| missing | Total | Low | Moderate | High | p-value | |
|---|---|---|---|---|---|---|
| Self-reported MG severity, n (%) | 1399 | 469 (33.5) | 690 (51.9) | 170 (12.8) | ||
| Depression (HADS) | ||||||
| No depression | 21 | 957 (69.2) | 392 (85.6) | 407 (60.1) | 100 (61.0) | < 0.001a |
| Depression | 421 (30.8) | 66 (14.4) | 270 (39.9) | 64 (39.0) | ||
| Mild | 217 (15.7) | 38 (8.3) | 142 (21.0) | 27 (16.5) | ||
| Moderate | 160 (11.6) | 23 (5.0) | 113 (16.7) | 34 (20.7) | ||
| Severe | 49 (3.5) | 5 (1.1) | 15 (2.2) | 3 (1.8) | ||
| Prediagnosed depression | 21 | 162 (11.6) | 35 (7.5) | 101 (14.6) | 21 (12.4) | 0.001b |
| Pharmacotherapye | 8 | 92 (56.0) | 20 (57.0) | 58 (57.0) | 14 (67.0) | |
| Psychotherapye | 28 | 47 (29.0) | 13 (37.0) | 31 (31.0) | 3 (14.0) | |
| Anxiety (HADS) | ||||||
| No anxiety | 22 | 903 (65.6) | 369 (80.6) | 379 (56.0) | 101 (61.6) | < 0.001a |
| Anxiety | 474 (35.5) | 89 (19.4) | 299 (44.0) | 63 (38.4) | ||
| Mild | 259 (18.8) | 58 (12.7) | 158 (23.3) | 28 (17.1) | ||
| Moderate | 162 (11.8) | 29 (6.3) | 118 (17.4) | 27 (16.5) | ||
| Severe | 53 (3.8) | 2 (0.4) | 23 (3.2) | 8 (4.9) | ||
| Prediagnosed anxiety | 24 | 80 (5.7) | 14 (3.0) | 52 (7.5) | 12 (7.1) | 0.004b |
| Pharmacotherapye | 397 | 45 (56.0) | 9 (64.0) | 29 (56.0) | 17 (24.0) | |
| Psychotherapye | 415 | 21 (26.0) | 3 (21.0) | 17 (33.0) | 1 (1.0) | |
| PTSD-7 after myasthenic crisis | 62 |
61 (10.7) (4.4% of the total) |
5 (1.1) | 42 (6.1) | 14 (8.2) | 0.020a |
| Prediagnosed PTSD | 41 | 62 (10.8) | 11 (2.4) | 39 (5.7) | 12 (7.0) | 0.001b |
PTSD Posttraumatic stress disorder.
P-values refer to overall group comparisons of patients with low, moderate and high MG severity. P-values < 0.05 are marked in bold numbers
aKruskal–Wallis-Test, bChi-square test.e % of prediagnosed cases.